相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Feng Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective
Dipti M. Karamchandani et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen et al.
ESMO OPEN (2018)
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report
Helen M. McGuire et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab
Ryota Tanaka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
Hisato Kawakami et al.
INVESTIGATIONAL NEW DRUGS (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. A. Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
Gary Joseph Doherty et al.
ESMO OPEN (2017)
Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.
Fernando Costa Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Jonathan H. Chen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Eduard Cornelis Verschuren et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L. Marthey et al.
JOURNAL OF CROHNS & COLITIS (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Systematic review: colitis associated with anti-CTLA-4 therapy
A. Gupta et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Ipilimumab-associated Hepatitis Clinicopathologic Characterization in a Series of 11 Cases
Melanie Johncilla et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
Marwan Ghabril et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim et al.
INVESTIGATIONAL NEW DRUGS (2013)
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Katarzyna D. Chmiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
